C Diff Drug Development

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company New York, New York--(Newsfile Corp. - September 13, 2021) - Acurx Pharmaceuticals (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company developing a new class of antibiotics that could present the most meaningful changes to that sector in more than four decades. Its lead program utilizes ibezapolstat to target the debilitating C. difficile infection. Other pipeline programs and d

Clostridioides difficile infection is the most common cause of nosocomial and antibiotic-associated diarrhea. C. difficile treatment is increasingly likely to fail, and the recurrence rate is high. Antimicrobial peptides are considered an alternative treatment for many infectious diseases, including …

EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health.

Grade 3 injection site redness led to the predefined stopping rules for 10 patients in the clinical trials.

Clostridioides difficile infection (CDI) is the primary cause of hospital-acquired diarrhea, and responsible for over 500,000 enteric infections a year in the United States alone. Although most patients with CDI are successfully treated with metronidazole or vancomycin, the high rate of recurrence i …

Almost a decade ago, American researchers performed experiments with poop to examine its effects, or rather the effects of the microbes in the stool on weight.

The discovered Amyloliquecidin GF610 is potentially useful in food, agricultural, or medical applications. The analytical approach followed may facilitate future discoveries of two-component lantibiotics, which are challenging compounds to detect and characterize.

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the start of a Phase 1 trial of LMN-Cdiff01, an orally delivered investigational biologic for treatment and prevention of recurrent C. difficile infection (CDI). The first trial participant was dosed at Coral Sea Clinical Research Institute (CSCRI) in Mackay, Queensland, Australia.

Protein-based targeting reagents, such as antibodies and non-antibody scaffold proteins, are rapidly inactivated in the upper gastrointestinal (GI) tract. Hydrochloric acid in gastric juice denatures proteins and activates pepsin, concentrations of which reach 1 mg/mL in the mammalian stomach. Two s …

Lumen Bioscience today announced the start of a Phase 1 trial of LMN-Cdiff01, an orally delivered investigational biologic for treatment and prevention of recurrent C. difficile infection (CDI).

2'FL and LNnT Exert Antipathogenic Effects against C. difficile ATCC 9689 In Vitro, Coinciding with Increased Levels of Bifidobacteriaceae and/or Secondary Bile Acids https://t.co/uIEXaqfuAW #cdi #cdiff— Dave Roberts (@CDifficile1) September 1, 2021

The treatment was also well-tolerated, with a similar safety profile to placebo, according to the investigators.

Clostridioides (also known as Clostridium) difficile is a Gram-positive anaerobic, spore producing bacterial pathogen that causes severe gastrointestinal infection in humans. The current chemotherapeutic options are inadequate, expensive, and limited, and thus inexpensive drug t …

This study investigated the prophylactic and therapeutic efficacies of baicalin (BC), a plant-derived flavone glycoside, in reducing the severity of Clostridioides difficile infection (CDI) in a mouse model. In the prophylactic trial, C57BL/6 mice were provided with BC (0, 11, and 22 mg/L in …

Ridinilazole is not currently approved for use by any regulatory authority.

This action follows a recently completed phase 2a clinical trial, which demonstrated that 100% of the 10 enrolled patients met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment as well as sustained clinical cure with no recurrence of CDI when examined on a 28-day follow-up visit.

When Takeda teamed up with Finch Therapeutics on inflammatory bowel disease (IBD), it planned to pick up programs after they’d finished phase 2 trials. Now, the Japanese pharma is moving that timeline up, taking the lead on an ulcerative colitis program before it hits the clinic.

Viruses have a menacing reputation for causing disease but some that target bacteria could actually benefit human health.

Almost five years after Seres Therapeutics slammed into a Phase II failure with its lead candidate, the microbiome pioneer is reporting another massive flop in ulcerative colitis. But like the last time, the company isn’t throwing in the towel just yet. Patients who took SER-287 — a consortia of bacteria

.@VedantaBio closes $68M #SeriesD #financing to advance defined #bacterial consortiaTargeting Ph3 #ClinicalTrials in patients at high risk of recurrent #Cdiff #infection; Ph2 study in #UlcerativeColitishttps://t.co/bj7jwfV4sW#microbiome #microbiota @WestwickeIR @bernatolle pic.twitter.com/8T1RY93fwV— DDNews Online (@DDNewsOnline) July 21, 2021

C. difficile is the most common cause of antibiotic-associated diarrhea in developed countries. New findings may help treat and even prevent it.

Read it now on PracticeUpdate.com